File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Multigene panel testing for hereditary breast and ovarian cancers: An analysis of 1303 BRCA-negative Chinese patients.

TitleMultigene panel testing for hereditary breast and ovarian cancers: An analysis of 1303 BRCA-negative Chinese patients.
Authors
Issue Date2018
PublisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/
Citation
2018 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, USA, 1-5 June 2018. In Journal of Clinical Oncology, 2018, v. 36 n. 15, Suppl., p. e13625 How to Cite?
AbstractBackground: Identification of other breast cancer susceptibility genes, other than BRCA1/2, in hereditary breast and ovarian cancers (HBOC) using multigene panels could help to assess cancer risk in patients. The spectrum and frequency of variants are different across ethnicity, it is therefore imperative to identify other HBOC genes in Chinese patients. Methods: 1,303 high-risk patients (negative for BRCA1, BRCA2, TP53 and PTEN) were selected from Hong Kong Hereditary Breast Cancer Family Registry and subjected to 30-gene panel by next-generation sequencing (Color Genomics). All detected pathogenic mutations were further validated by bi-directional DNA sequencing and co-analyzed by our in-house developed bioinformatics pipeline. Results: Sixty-one pathogenic or likely pathogenic variants were identified (4.68%), which correspond to 12 different cancer predisposition genes. Majority of the carriers (77.05%) had early-onset of breast cancer (age <45), 29.51% had family members with breast cancer and 13.11% were triple-negative. The most common mutated genes were PALB2 (1.38%), RAD51D (0.84%) and ATM (0.77%). Moreover, over 29% of patients had variant of unknown significance (VUS) in these genes, which account for 323 types. Conclusions: Additional preventive measures and clinical management are recommended in 90% of the mutation-positive cases. Multigene panel testing is an alternative strategy in the diagnosis of HBOC, this could help to estimate the cancer risk and aid the development of effective treatments.
Persistent Identifierhttp://hdl.handle.net/10722/271344
ISSN
2017 Impact Factor: 26.36
2015 SCImago Journal Rankings: 9.204

 

DC FieldValueLanguage
dc.contributor.authorKwong, A-
dc.contributor.authorShin, VY-
dc.contributor.authorAu, CH-
dc.contributor.authorHo, YSC-
dc.contributor.authorChan, TL-
dc.contributor.authorMa, E-
dc.date.accessioned2019-06-24T01:08:03Z-
dc.date.available2019-06-24T01:08:03Z-
dc.date.issued2018-
dc.identifier.citation2018 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, USA, 1-5 June 2018. In Journal of Clinical Oncology, 2018, v. 36 n. 15, Suppl., p. e13625-
dc.identifier.issn0732-183X-
dc.identifier.urihttp://hdl.handle.net/10722/271344-
dc.description.abstractBackground: Identification of other breast cancer susceptibility genes, other than BRCA1/2, in hereditary breast and ovarian cancers (HBOC) using multigene panels could help to assess cancer risk in patients. The spectrum and frequency of variants are different across ethnicity, it is therefore imperative to identify other HBOC genes in Chinese patients. Methods: 1,303 high-risk patients (negative for BRCA1, BRCA2, TP53 and PTEN) were selected from Hong Kong Hereditary Breast Cancer Family Registry and subjected to 30-gene panel by next-generation sequencing (Color Genomics). All detected pathogenic mutations were further validated by bi-directional DNA sequencing and co-analyzed by our in-house developed bioinformatics pipeline. Results: Sixty-one pathogenic or likely pathogenic variants were identified (4.68%), which correspond to 12 different cancer predisposition genes. Majority of the carriers (77.05%) had early-onset of breast cancer (age <45), 29.51% had family members with breast cancer and 13.11% were triple-negative. The most common mutated genes were PALB2 (1.38%), RAD51D (0.84%) and ATM (0.77%). Moreover, over 29% of patients had variant of unknown significance (VUS) in these genes, which account for 323 types. Conclusions: Additional preventive measures and clinical management are recommended in 90% of the mutation-positive cases. Multigene panel testing is an alternative strategy in the diagnosis of HBOC, this could help to estimate the cancer risk and aid the development of effective treatments.-
dc.languageeng-
dc.publisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/-
dc.relation.ispartofJournal of Clinical Oncology-
dc.relation.ispartof2018 American Society of Clinical Oncology (ASCO) Annual Meeting-
dc.titleMultigene panel testing for hereditary breast and ovarian cancers: An analysis of 1303 BRCA-negative Chinese patients.-
dc.typeConference_Paper-
dc.identifier.emailKwong, A: avakwong@hku.hk-
dc.identifier.emailShin, VY: vyshin@hku.hk-
dc.identifier.emailChan, TL: tlchan@hku.hk-
dc.identifier.authorityKwong, A=rp01734-
dc.identifier.authorityShin, VY=rp02000-
dc.identifier.authorityChan, TL=rp00418-
dc.identifier.doi10.1200/JCO.2018.36.15_suppl.e13625-
dc.identifier.hkuros298255-
dc.identifier.volume36-
dc.identifier.issue15, Suppl.-
dc.identifier.spagee13625-
dc.identifier.epagee13625-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats